What's hot
View all perspectives
What's Hot
Rheumatoid Arthritis Comorbidities
Dr. Jonathan Kay reviews rheumatoid arthritis studies presented on day at EULAR 2022. Specifically, he discusses abstracts OP0132, OP0135 and OP0138.
Watch video →
Increasing Secukinumab Dose in Ankylosing Spondylitis Nonresponders
Dr. Peter Nash discusses abstract OP0023 from EULAR 2022.
Watch video →
DMARDS, Prednisone, Pregnancy, OH MY!
Dr. Kathryn Dao discusses abstracts POS1405, POS0696 and OP0130 presented at the EULAR 2022 meeting. Watch more videos from EULAR 2022 here: https://rheumnow.com/videos.
Watch video →
Breathing New Insight into RA Interstitial Lung Disease
Dr. Jonathan Kay reviews EULAR 2022 abstracts OP0132, OP0306, and OP0307.
Watch video →
EULAR 2022 - Day 4 Faculty Panel Recap
Dr. David Liew and Dr. Jack Cush discuss day 4 of EULAR 2022. LB0001, LB0002, LB0004, and LB0006.
Watch video →
Getting to the Heart of JAK Inhibitors
Dr. Jonathan Kay reviews rheumatoid arthritis sessions and abstracts from day 3 at EULAR 2022. Abstracts reviewed: OP0266; OP0258; and OP0269.
Watch video →
EULAR 2022 - Day 3 Faculty Panel Recap
Drs. Jack Cush, Janet Pope, Aurelie Najm and Yuz Yusof discuss highlights from Day 3 of EULAR 2022.
Watch video →
Deucravacitinib at EULAR 2022
Dr. Peter Nash provides and update on the TYK2 inhibitor, Deucravacitinib with reports on: - Safety of Deucravacitinib https://bit.ly/3NtZQxe - Deucravacitinib in SLE https://bit.ly/3Mh5nG0
Watch video →
Aurelie Najm AurelieRheumo
3 years 6 months ago
Remission in PsA
❗️According to DAS28-CRP
*22% never achieve a state of remission
*< than half achieved at least stage of SR
❗️According to DAPSA28
*73% never achieve a state of remission
Are we that bad? Or do we need different measures? Or both?
@RheumNow
OP0262 #EULAR2022 https://t.co/6aeNW17VWg
Aurelie Najm AurelieRheumo
3 years 6 months ago
📈 Machine learning driven phenotyping in PsA
4 clusters of pts treated w/ Guselkumab identified 📊
1 cluster w/ higher BL disease burden associated w/ worst response
As fancy as it gets, not sure how to implement these in practice 🧐
@RheumNow #EULAR2022 OP0259 https://t.co/75X4ZqeEQJ
Janet Pope Janetbirdope
3 years 6 months ago
@RichardPAConway @CatherineL_Hill @rheum_cat @RheumNow @KDAO2011 @uptoTate @AurelieRheumo Hello. @RheumNow reports @eular_org #EULAR2022 and teaches many. I learn as a tweeter. Way to go for all people tweeter this meeting. https://t.co/W3DuoVdfby
Md Yuzaiful Md Yusof Yuz6Yusof
3 years 6 months ago
When Tweeps meet IRL #EULAR2022 #queensjubilee2022 @YelizPrior @DrMiniDey @chriswincup https://t.co/cnTFw2jjVd
Richard Conway RichardPAConway
3 years 6 months ago
Sanchez-Bilboa at al. IV vs SC tocilizumab in 471 GCA patients. Equal efficacy. The authors report more adverse events with IV but actually this was purely due to longer follow up and per patient years it was the same. @RheumNow #EULAR2022 POS0272 https://t.co/2h7iIkMxjW
Dr. John Cush RheumNow
3 years 6 months ago
Just try and get into the great Tivoli Gardens after a day at #EULAR2022 https://t.co/qsGln5nH6S
Richard Conway RichardPAConway
3 years 6 months ago
Yusof et al @Yuz6Yusof COVID-19 in RTX treated patients. Significant efficacy of vaccination in both overall and severe COVID rates. Vaccination decreased risk HR 0.13 (0.03-0.51). Number comorbidities and low IgG increase risk @RheumNow #EULAR2022 OP0250 https://t.co/yD1tvs1UYt https://t.co/23XTtPb8fD
ARD & RMD Open ARD_BMJ
3 years 6 months ago
Pharmacodynamic effect of sequential #belimumab and #rituximab therapy in patients with systemic #lupus: BLISS-BELIEVE study
#EULAR2022
>CR https://t.co/AgBBuqYatW
David Liew drdavidliew
3 years 6 months ago
#EULAR2022 virtual from my Copenhagen apartment this morning - you can’t watch three concurrent streams in person! @RheumNow https://t.co/Z74EOPn7kW
Richard Conway RichardPAConway
3 years 6 months ago
WIN-Lupus. RCT of stopping treatment in SLE. All on HCQ. Randomised to stop Aza/MMF after being stable on for 2-3 years. Relapse proliferative nephritis in 25% vs 10%. Severe SLE flare 32% vs 13%. @RheumNow #EULAR2022 OP0280 https://t.co/IAcCoKw1YI
Emre Bilgin, MD dr_emrebilgin
3 years 6 months ago
It was a pleasure to eat with editors of @RheumJnl at the first evening of #EULAR2022 @LatikaGupta_ @drdj @docrota @SteZhao @ElenaNikiUK
Best Rheumatology journal 🥳🥳 https://t.co/oTDWRUh0Fb
David Liew drdavidliew
3 years 6 months ago
So maybe, when it comes to delivering healthcare and telemedicine, we need to think about quality and efficiency? #EULAR2022 @RheumNow https://t.co/JMbQ1ZUB0o
David Liew drdavidliew
3 years 6 months ago
and, Robert Landewe argues, telemedicine is merely exchanging parcels of information.
Life visits deliver the chance for empathy #EULAR2022 @RheumNow https://t.co/2CKTJHfF7A
David Liew drdavidliew
3 years 6 months ago
Quality patient communication is actually critical to outcome #EULAR2022 @RheumNow https://t.co/37Z7hwrWmX
David Liew drdavidliew
3 years 6 months ago
What's the argument against that?
Fundamentally, empathy. The patient experience isn't just a product of miracle drugs - over time it's a multitude of factors that are what leads to happy patients
#EULAR2022 @RheumNow https://t.co/8GwhdT8cit
Poster Hall